In alignment with the Trump administration’s efforts to lower drug prices, Amgen today launched AmgenNow, a direct-to-patient program offering evolocumab (Repatha) at a monthly price of $239, nearly ...
The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.
Pharmaceutical Technology on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.
Madrid, Spain – 1 September 2025: After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to ...
Addition of the PCSK9 inhibitor evolocumab to statin therapy after cardiac bypass surgery did not improve 24-month graft patency in the NEWTON-CABG CardioLink-5 trial. Subodh Verma, MD, cardiac ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback